炎症性肠病患者应用生物制剂和小分子制剂发生潜伏结核感染再激活风险现状和应对  

The risk and management of latent tuberculosis infection reactivation in patients with inflammatory bowel disease using biological agents and small molecule agents

作　　者：梁浩正 阮戈冲 储晓天 杨红 Liang Haozheng;Ruan Gechong;Chu Xiaotian;Yang Hong(Department of Gastroenterology,Peking Union Medical College Hospital,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院、北京协和医学院、北京协和医院消化内科,北京100730

出　　处：《中华炎性肠病杂志（中英文）》2023年第1期55-59,共5页Chinese Journal of Inflammatory Bowel Diseases

摘　　要：炎症性肠病(IBD)是一类肠道慢性炎性免疫性疾病。近年来不同靶点的生物制剂和小分子制剂用于治疗IBD,同时也带来机会性感染,其中潜伏结核感染再激活的危害较大。我国是结核病高发地之一,临床医生对生物制剂和小分子制剂诱发的潜伏结核感染再激活高度重视。本文回顾生物制剂和小分子制剂等药物相关的潜伏结核感染再激活的风险,以及国内外指南的诊疗推荐,期望能为IBD合并潜伏结核感染的患者在应用这些药物时提供参考。Inflammatory bowel disease(IBD)is a kind of chronic inflammatory immune disease of the intestine.In recent years,biologics and small molecule agents with different targets have been used for the treatment of IBD.However,it also brings concerns about opportunistic infections,among which the reactivation of latent tuberculosis infection is more harmful.China is still one of the epidemic areas of tuberculosis,and clinicians attach great importance to the reactivation of latent tuberculosis infection induced by biologics and small molecule agents.This paper reviews the risk of latent tuberculosis infection reactivation associated with biologics and small molecule agents and the recommendation of the guideline.It is expected to provide a reference for the application of these medications in patients with inflammatory bowel disease complicated by latent tuberculosis infection.

关 键 词：炎症性肠病 生物制剂 小分子制剂 潜伏结核感染 

分 类 号：R574[医药卫生—消化系统]